FDA Accepts for Filing Mylan's ANDA for Generic Copaxone(R)

Mon, 09/14/2009 - 4:33am
Mylan Inc. has announced that the FDA has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone(R), a product indicated for the treatment of multiple sclerosis. As previously announced, Mylan entered into a license and supply agreement with NATCO Pharma Ltd. (NATCO) which granted Mylan exclusive distribution rights for Glatiramer Acetate pre-filled syringes in the U.S. and all major markets in Europe, Australia, New Zealand, Japan and Canada. The agreement also includes an option to potentially expand into additional territories.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.